The mean of analysts' price targets for Edgewise Therapeutics (EWTX) points to a 174.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong ...

We recently published a list of the 11 Most Promising Small-Cap Stocks According to Analysts. In this article, we are going to take a look at where Edgewise Therapeutics Inc.

Hypertrophic cardiomyopathy (HCM), a condition characterized by abnormal thickening of the heart muscle, affects countless individuals worldwide. Recent clinical trials have sparked renewed hope for ...

Edgewise Therapeutics, Inc. is trading lower this time around since I last wrote about it. Especially, in light of today's events of both 2 safety issues of AF along with the $200 million in cash ...

Shares of Edgewise Therapeutics fell sharply Wednesday after the company released data for its latest clinical trial. The drug accomplished its main goal, but side effects reported by some ...

The initial data read-out from Part D is expected in the second half of 2025, with Phase 3 initiation planned for the first half of 2026. EDG-7500 Top-line Data Webcast Event Members of the Edgewise ...

In participants with nonobstructive HCM, EDG-7500 administration resulted in a dose-dependent reduction in NT-proBNP, with a 42% mean decrease from baseline at 100 mg. A positive trend in an ...

100 mg dose led to a 71% mean reduction in resting LVOT gradient and 58% in provokable gradient. NT-proBNP levels dropped 62% in obstructive HCM and 42% in nonobstructive HCM at 100 mg. Market ...

In participants with nonobstructive HCM, EDG-7500 administration resulted in a dose-dependent reduction in NT-proBNP, with a 42% mean decrease from baseline at 100 mg. A positive trend in an ...

In addition, the 100-mg cohort also saw a 62% mean reduction from baseline in NT-proBNP, a biomarker of heart failure. In participants with nonobstructive HCM, 100 mg of EDG-7500 administration ...

Members of the Edgewise management team will hold a live webcast on Wednesday, April 2, 2025, at 8:30 a.m. ET to discuss the top-line data, and will be joined by leading cardiology experts, Anjali ...